Pain and Inflammation Research

Although separate conditions, pain and inflammation are nearly always associated with each other. Pain is defined by the International Association for the Study of Pain (IASP) as 'an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage'. Inflammation is the tissue's immunologic response to injury, characterized by mobilization of white blood cells and antibodies, swelling, and fluid accumulation.

Pain and Inflammation Research Products Areas

Products for Pain and Inflammation Research - Page 31

Cat.No. Product Name Information/Activity
BCC6906 QX 222 5369-00-6
BCC6889 QX 314 bromide QX-314 bromide is a membrane-impermeable permanently charged sodium channel blocker.
BCC7326 QX 314 chloride QX-314 chloride is a membrane-impermeable permanently charged sodium channel blocker.
BCC7844 Ralfinamide mesylate Ralfinamide mesylate (FCE-26742A mesylate) is an orally available Na+ channel blocker derived from α-aminoamide, with function of suppressing pain.
BCC7847 Sipatrigine Sipatrigine, a neuroprotective agent, is a glutamate release inhibitor, voltage-dependent sodium channel and calcium channel inhibitor, penetrating the central nervous system. Has potential to treat focal cerebral ischemia and stroke.
BCC6179 TC-N 1752 1211866-85-1
BCN1035 Tetrodotoxin Tetrodotoxin is a highly selective sodium channel blocker, with IC50 of 33 nM for Nav1.6.
BCN2609 Vinpocetine Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na+ channels. The IC50 value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting IκB kinase complex (IKK), and has been widely used for the treatment of cerebrovascular disorders.
BCC1048 β-Pompilidotoxin Slows neuronal Na+ channel inactivation
BCC5078 Rufinamide Rufinamide(E 2080; CGP 33101; RUF 331) is a new antiepileptic agent that differs structurally from other antiepileptic drugs and is approved as adjunctive therapy for Lennox-Gastaut syndrome (LGS).